We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The cancer moonshot’s blue ribbon panel made 10 recommendations to the National Cancer Advisory Board to guide scientific direction for the national research initiative, specifically organizing an immunotherapy clinical trials network. Read More
Destiny Pharma reported positive safety and efficacy results from an NIH-supported clinical trial of exeporfinium chloride, for the prevention of post-surgical staphylococcal infections. Read More
Heart Metabolics launched an open-label Phase IIb study of perhexiline in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure with preserved left ventricular function. Read More
Merck is suspending development of its osteoporosis candidate after an analysis of its Phase III fracture outcomes study demonstrated that the therapy increases the risk of strokes. Read More
A Phase III study of Tecentriq immunotherapy met its primary endpoints by showing improvements in overall survival, regardless of PD-L1 status, when compared with docetaxel chemotherapy in locally advanced or metastatic non-small cell lung cancer. Read More